As an industry leader in lipid delivery technology, Scindy Pharmaceutical leverages its deep understanding of lipid chemistry and proprietary advanced lipid material platform to achieve breakthrough applications of LNP technology. We proudly introduce the NeoLNP™ series of innovative cell transfection products, marking a new era of precise and efficient RNA delivery.

The NeoLNP™ Immune Cell Line CRISPR Kit (SDR2100) is developed for commonly used immune cell lines, achieving >90% transfection efficiency in cell lines like Jurkat, THP-1, and DC2.4 through modular lipid library construction and formulation optimization. Its unique endogenous delivery mechanism ensures high RNA co-transfection activity while elevating cell viability to industry-leading levels, providing standardized solutions for immune cell line CRISPR editing.

Breakthrough for Hard-to-Transfect Cells - NeoLNP™ SDR2100: The Expert in Immune Cell Editing

• Efficient Co-Transfection: Single delivery of Cas9 mRNA + sgRNA ensures synchronized expression, with transfection efficiency up to 90%.

• Ultra-Low Toxicity: Biodegradable lipid materials ensure high cell viability.

• High Payload Capacity: Supports multi-gene co-delivery, such as Cas9 mRNA + Reporter RNA + sgRNA.

• High Convenience: Ready-to-use LNP enables instant RNA encapsulation through simple mixing, requiring no equipment or complex operations.

• Broad Applicability: Covers immune cell lines like Jurkat, THP-1, Raw, U266, and DC2.4.

Parameter	NeoLNP™	Viral Vector	Electroporation	RNP Complex
Delivery Efficiency	High (≥90% in immune cell	High in dividing cells	High in T cells	Varies by cell type
Cytotoxicity	Low (biodegradable lipids)	Immune response/insertional mutagenesis	Electrical damage	High RNP concentration toxicity
Immunogenicity	None (no viral components)	High (adenovirus)	None	None
Applicable Cell Types	Broad (Jurkat, THP-1, RAW264, etc.)	Mainly dividing cells	Hard-to-transfect cells (e.g., T cells)	Requires optimization
Payload Capacity	High (15 kb mRNA + sgRNA co-delivery)	Limited (AAV ≤4.5 kb)	Medium (sequential delivery)	Low (only Cas9 protein + sgRNA)
Preparation Convenience	Ready-to-use LNP, no equipment needed	Complex (viral packaging/purification)	Requires electroporation equipment	Requires pre-assembled RNP

Efficient Co-Transfection: Unique endogenous transport mechanism enables efficient mRNA + sgRNA transfection in traditionally hard-to-transfect cells.

• NeoLNP™: Ready-to-use LNP encapsulates Cas9 mRNA and sgRNA, utilizing endogenous transmembrane transport and endosomal escape for efficient co-delivery.

• Viral Vector: Relies on viral shells (e.g., AAV, lentivirus) for cell entry, with risks of integration or immunogenicity.

• Electroporation: Uses electrical pulses to breach cell membranes, requiring specialized equipment and causing cell damage.

• RNP Complex: Pre-assembled Cas9 protein + sgRNA, with no nucleic acid residue but potential toxicity at high concentrations.

High Payload Capacity: Supports 15 kb mRNA + sgRNA co-delivery, expandable to multi-gene delivery.

• NeoLNP™: Supports mRNA + sgRNA co-delivery, ensuring synchronized expression.

• Viral Vector: Limited by AAV (4.5 kb) or lentivirus (8 kb), requiring separate packaging.

• Electroporation: 10-12 kb, requiring optimization of mRNA/sgRNA ratios.

• RNP Complex: Limited to Cas9 protein + sgRNA, unable to deliver large nucleic acids.

High Convenience: Ready-to-use LNP enables zero-threshold RNA-LNP preparation.

• NeoLNP™: 1-minute RNA-LNP encapsulation, 12+ months storage at 4°C, no specialized skills needed.

• Viral Vector: 2-4 weeks for packaging/purification, stored at -80°C, requires biosafety permits.

• Electroporation: 1 hour for parameter optimization, requires equipment training.

• RNP Complex: 2 hours for protein-RNA assembly, stored at -80°C, requires protein purification skills.

Broad Applicability: Covers immune cell lines like Jurkat, THP-1, U266, DC2.4, and RAW264.7. Validated cell lines include:

Superior CRISPR Gene Editing Performance in Immune Cell Lines

SDR2100 NeoLNP™, Lipofectamine™2000, TransIT®-mRNA, and Lipofectamine™ MessengerMAX™ in a 24-well plate, co-transfect 0.5µg Cas9 mRNA and 0.5µg gRNA into Jurkat cells. After 48 hours, T7E1 assay verifies cleavage efficiency.

SDR2100 NeoLNP™ significantly outperforms Lipofectamine™2000, TransIT®-mRNA, and MessengerMAX™.

NeoLNP™ Simple and User-Friendly RNA-LNP Encapsulation Solution

The NeoLNP™ Transfection Kit offers an innovative RNA-LNP encapsulation solution. Compared to traditional methods, NeoLNP™ requires no complex equipment, achieving zero-loss RNA encapsulation through a simple one-step mixing process, significantly reducing preparation time (1 minute vs. 10 hours). This technology overcomes the technical barriers of traditional LNP preparation, delivering optimized, standardized LNP formulations to researchers, providing a new experience for RNA transfection.